#	Pagina
attuale pagina	/open-h2020/projects/224648/index.html
-1	/open-h2020/per-topic/utilities/list/index.html
-2	/open-h2020/projects/200181/index.html
-3	/open-h2020/projects/226111/index.html
-4	/open-h2020/projects/199028/results.html
-5	/open-h2020/projects/222524/index.html
-6	/open-h2020/projects/225659/index.html
-7	/open-h2020/projects/204272/index.html
-8	/open-h2020/per-topic/igt/list/index.html
-9	/open-h2020/projects/213269/index.html
-10	/open-h2020/projects/198930/index.html

Opendata, web and dolomites

BIOXPLOR SIGNED

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

BIOXPLOR project word cloud

Explore the words cloud of the BIOXPLOR project. It provides you a very rough idea of what is the project "BIOXPLOR" about.

responder revenue customers tested pilots partnered proteins company score 2021 successfully 2019 multiyear deploying march seal shown savings 2m immunoassays pipeline id last reduces projected 5x biotech inflammatory orders tests patient negotiating submission excellence novartis diseases submissions super pharma ai bayer 25x accelerates acceleration 100k indication 70 09 secondary rare inflammation solution tlr platform trials antibodies space oncology revenues companies edemedx genomes 2018 leads programs discovery gained biomarker stage clinical recombinant progress environments institutes bioxplor building expansion cognitive primary forum requested 13 stratification merck skydeck drug biosimilars eur500k eur750k time academic software repositioning contracts abcam 15 november data berkeley acquiring uc

Project "BIOXPLOR" data sheet

The following table provides information about the project.

Coordinator	BIOXPLOR LIMITED Organization address address: 9C THE BOTTLEWORKS city: Dublin postcode: Dublin 4 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	https://bioxplor.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-07-01 to 2019-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BIOXPLOR LIMITED BIOXPLOR LIMITED Organization address address: 9C THE BOTTLEWORKS city: Dublin postcode: Dublin 4 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Dublin)	coordinator	50˙000.00

Map

Project objective

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies). BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOXPLOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOXPLOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat